CytomX Therapeutics Inc

Explore how CytomX insider sales, including Chu Yu‑Waye’s recent sell‑off, affect share price and investor confidence, and why the company’s oncology pipeline still holds long‑term upside.

Insider sales at CytomX reveal routine RSU‑driven liquidity amid market turbulence, yet the company’s strong pipeline and recent offering suggest long‑term upside for investors.

Insider sales at CytomX Therapeutics signal routine tax moves, not managerial doubt—yet the cluster may add short‑term selling pressure. Investors should weigh this liquidity dip against the company’s strong Varseta‑M pipeline and ongoing funding ne…